References

1. Doukas MA: Human immunodeficiency virus associated anemia. Med Clin North Am 76:699, 1992.

2. Groopman JE: Management of hematologic complications of human immunodefrciency virus infection. Rev Infect Dis 12:931, 1990.

3. Mir N, Costello C, Luckit J, Lindley R: HIV-disease and bone marrow changes: A study of 60 cases. Eur J Haematol 42:339, 1989.

4. Frontiera M, Myers AM: Peripheral blood and bone marrow abnormalities in the acquired immunodeficiency syndrome. West J Med 147:157, 1987.

5. Zon LI, Arkin C, Groopman, J: Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol 66:251, 1987.

6. Calenda V, Chermann JC: The effects of HIV on hematopoiesis. Eur J Haematol 48:181, 1992.

7. Zauli G, Re MC, Visani G, Furlini G, Mazza P, Vignoli M, LaPlaca M: Evidence for a human immunodeficiency virus type-1 mediated suppression of uninfected hematopoietic (CD34⁺) cells in AIDS patients. J Infect Dis 166:710, 1992.

8. Zauli G, Davis BR, Re MC, Visani G, Furlini G, LaPlaca M: Tat protein stimulates production of transforming growth factor-beta 1 by bone marrow macrophages: A potential mechanism for human immunodeficiency virus-1-induced hematopoietic suppression. Blood 80:3036, 1992.

9. Maciejewski JP, Weichold FF Young NS: HIV-1 suppression of hematopoiesis in vitro mediated by envelope glycoprotein and TNF-. J Immunol 153:4303, 1994.

10. Spivak JL, Barnes DC, Fuchs E, Quinn TC: Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 261:3104, 1989.

11. Camacho J, Poveda F, Zamorano AF, Valencia ME, Vázquez JJ, Arnalich F: Serum erythropoietin levels in patients with advanced human immunodeficiency virus infection. Br J Haematol 82:608, 1992.

12. Horsburgh CR: Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 324:1332, 1991.

13. Naides SJ, Howard ET, Swack NS, True CA, Stapleton JT: Parvovirus B19 infection in human immunodeficiency virus type-1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis 168:101, 1993.

14. Richman DD, Fischl MA, Grieco MH, Gottleib MS, Volderding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Nusinoff-Lehrman S, and the AZT Collaborative Working Group: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blinded, placebo controlled trial. N Engl J Med 317:192, 1987.

15. Faulds D, Heel RC: Ganciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficiency in cytomegalovirus infections. Drugs 39:597, 1990.

16. Keisu M, Wiholm BE, Palmblad J: trimethoprim-sulphamethoxazole-associated blood dyscrasias. Ten years' experience of the Swedish spontaneous reporting system. J Intern Med 228:353, 1990.

17. Remacha AF, Riera A, Cadafalch J, Gimferrer E: Vitamin B-12 abnormalities in HIV-infected patients. Eur J Haematol 47:60, 1991.

18. Ciaffoni S, Luzzati R, Roata C, Turrini A, Antonello O, Aprili G: Presence and significance of cold agglutinins in patients with HIV infection. Haematologica 77:233, 1992.

19. Cleveland RP, Liu YC: CD4 expression by erythroid precursor cells in human bone marrow. Blood 87:2275, 1996.

20. Morfeldt-Månson L, Böttiger B, Nilsson B, von Stedingk LV: Clinical signs and laboratory markers in predicting progression to AIDS in HIV-1 infected patients. Scand J Infect Dis 23:443, 1991.

21. Ellaurie M, Burns ER, Rubinstein A: Hematologic manifestations in pediatric HIV infection: Severe anemia as a prognostic factor. Am J Pediatr Hematol Oncol 12:449, 1990.

22. Salort Y, Dupon M, Chene G, Farbos S, Nouts C, Marimoutou C: Predictors of mortality in patients with advanced immunodeficiency, in Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997 (abstr 528).

23. Henry DH, Beall GN, Benson CA, Carey J, Cone LA, Eron LJ, Fiala M, Fisch MA, Gabin SS, Gottleib MS: Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med 117:739, 1992.

24. Farizo KM, Buehler JW, Chamberland ME, Whyte BM, Froelicher ES, Hopkins SG, Reed CM, Mokotoff ED, Cohn DL, Troxler S, Phelps AF, Berkelman RL: Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 267: 1798, 1992.

25. Laboratory values of clinical importance, in Petersdorf RG, Adams RD, Braunwald E, Isselbacher KJ, Martin JB, Wilson JD (eds): Harrison's Principles of Internal Medicine (ed 10). New York, NY, McGraw-Hill, 1983, pA-3.

26. Sahai J, Gallicano K, Pakuts A, Cameron DW: Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 169:1103, 1994.

27. Fraser I, Macintosh I, Wilkins EG: Prophylactic effect of co-trimoxazole for Mycobacterium avium complex infection: A previously unreported benefit. Clin Infect Dis 19:211, 1994 (letter).

28. Petrakis NL, Wiesenfeld SL, Sams BJ, Collen MF, Cutler JL, Siegelaub AB: Prevalence of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 282:767, 1970.

29. Tarlov AR, Brewer GJ, Carson PE, Alving AS: Primaquine sensitivity. Arch Intern Med 109:209, 1962.

30. Todd P, Samaratunga IR, Pembroke A: Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy. Clin Exp Dermatol 19:217, 1994.

31. Allen SD, Wilkerson JL: The importance of glucose-6-phosphate dehydrogenase screening in a urologic practice. J Urol 107:304, 1972.

32. Constantopoulos A, Economopoulos P, Kandylas J: Fulminant diarrhea and acute hemolysis due to glucose-6-phosphate deficiency in salmonellosis. Lancet 1:1522, 1973.